N/A N=94 Bioness® StimRouter™ Neuromodulation System for Chronic Pain Therapy
Chronic Pain
Primary: Brief Pain Inventory (BPI): Number of Participants With a Pain Reduction of Greater Than or Equal to 30% — 17; 5 participants — p=0.0048
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=140 Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery
Breast Cancer Patient
Primary: Change in Neuropathic Pain Score at 2 Months (Numeric Rating Scale 0-10) — 4.1; 4.6 units on a scale
Phase 2 N=24 Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury
Spinal Cord Injuries
Primary: Brief Pain Inventory, Worst Pain — 8.9; 9.7 score on scale
N/A N=13 BlueWind Medical Reprieve System for the Treatment of PNP
Peripheral Neuropathy
Primary: The Incidence of System and/or Procedure Related Serious Adverse Events (SAEs). — 1 Participants
N/A N=38 Project Relief: Developing Brain Stimulation as a Treatment for Chronic Pain
Chronic Pain · Chronic Lower Back Pain · Back Pain
Primary: Changes in Patient Reported Pain and Discomfort — 47; 13; -30; -18 percent change from baseline
Phase 3 N=44 Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Spinal Cord Injuries · Neuropathic Pain
Primary: The International Spinal Cord Injury Pain Data Set (ISCIPBDS) (Version 2.0) - Change in Average Worst Neuropathic Pain Intensity — -0.5; -0.5 points
Phase 3 N=70 A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin
Pain · Multiple Sclerosis
Primary: Change From Baseline in Mean Pain Box Scale-11 Score at 3 Weeks. — -1.3; -0.9 units on a scale — p=0.332
N/A N=26 Surgical Treatment of Post-surgical Mastectomy Pain Utilizing the Regenerative Peripheral Nerve Interface
Post-Mastectomy Chronic Pain Syndrome
Primary: Change in Pain Level — 6.9; 0.6; 4.4; 2.5 score on a scale
Phase 3 N=65 An Implantable Spinal Cord Stimulation Pain Management System
Chronic Pain · Pain, Intractable · Pain
Primary: Change in Visual Analog Scale (VAS) Score From Baseline to 2 Week Post Initial Fitting. — 35 participants with > 50% VAS improvement
Phase 4 N=86 Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization
Chronic Pain
Primary: Pain Intensity — 11; 29 Participants
Phase 2 N=131 A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.70; -1.81 score on a scale
N/A N=10 Empower Opioid Misuse & Chronic Pain
Chronic Pain · Opioid Use
Primary: Pain Intensity Score Measures — 55; 57 Score on a scale
N/A N=8 Peripheral Sensory Input in Central Post Stroke Pain (CPSP)
Central Post Stroke Pain
Primary: Reduction in Spontaneous Pain Intensity After a Peripheral Nerve Block. — 6.5; 0.0 units on a scale
Phase 4 N=20 Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
Trigeminal Neuralgia · Glossopharyngeal Neuralgia
Primary: Change in Pain Score — -0.6224; -1.005; -0.8102; -1.079 score on a scale
Phase 3 N=240 Pregabalin Peripheral Neuropathic Pain Study
Diabetic Neuropathies · Neuralgia
Primary: Daily Pain Rating Scale (DPRS)- Mean Pain Score (ITT Population) — 4.63; 5.13 score on scale — p=0.049
N/A N=133 Noninvasive Peripheral Nerve Stimulation for Medication-Refractory Primary RLS (The RESTFUL Study)
Restless Legs Syndrome
Primary: Number of Subjects for Which the Clinician Reported "Much Improved" or "Very Much Improved" on the Clinical Global Impressions-Improvement (CGI-I) Scale for TOMAC…
Phase 2 N=155 Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.50; -1.35 score on a scale
Phase 2 N=125 Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the NRS — -1.98; -1.56 score on a scale
N/A N=42 Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
Chronic Migraine
Primary: Proportion of Participants With Reduction of Migraine Headache at 2 Hours Post Treatment — 19 Participants
Phase 2 N=240 Prospective, Randomized Controlled Trial on Perioperative Pregabalin to Reduce Late-onset CRPS After TKA
CRPS
Primary: Epidural Medication Consumption Rate — 6.40; 5.77 mL/h — p=0.003
N/A N=161 Symptom Management Efficacy Study to Reduce Distal Neuropathic Pain
Neuropathic Pain · HIV Neuropathy · HIV/AIDS
Primary: Gracely Pain Scale (GPS) — -2.51; -1.96; -2.38; -0.99 GPS pain score on a scale
Phase 2 N=7 An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain
Chronic Refractory Neuropathic Pain
Primary: Number of Subjects Reporting At Least 1 Treatment-Emergent Adverse Event (TEAE) During The Treatment Period. — 7 participants
N/A N=26 Pregabalin in CIPN
Neuropathy · Pain
Primary: Change in Spontaneous Pain Intensity as a Function of Baseline MPT — -0.0179; -0.0172 Pearson correlation coefficient
Phase 3 N=75 Neuropathic Pain Management
Diabetic Neuropathies · Polyneuropathies
Primary: Mean Neuropathic Pain Score at Visit 3 (Week 1) — 51.00; 50.70 Units on a Scale
N/A N=40 Clinical Outcomes Study Using a New Implantable Neurostimulation System for Chronic Intractable Pain
Chronic Pain
Primary: Proportion of Subjects Satisfied With Treatment at 90 Days Post-IPG Implantation — 32 Participants
Phase 2 N=132 Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)
Early Phase 1 N=22 Developing Brain Stimulation as a Treatment for Chronic Pain in Opiate Dependent
Chronic Pain · Opiate Dependence · Lower Back Pain
Primary: Change in Quantitative Pain Testing Following Active TMS Compared to Baseline — 1.4; .3 Change from Baseline (degrees C) — p=.83
Phase 2 N=6 CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT)
Radiculopathy
Primary: Change in Opioid Analgesic Plasma Levels — 10.86; -11.4 ng/mL
N/A N=47 Cognitive Behavioral Therapy for Diabetic Neuropathic Pain
Diabetic Peripheral Neuropathic Pain
Primary: Numeric Rating Scale (NRS) Pain Intensity — -0.83; -0.45 units on a scale — p=0.47
N/A N=22 Scrambler Trial for Pain in NMOSD
Neuromyelitis Optica
Primary: Acceptability as Assessed by the Number of Participants Responding Yes to a Question — 7; 5 Participants